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Background: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has an extremely poor prognosis and
there is currently no effective treatment for this condition. Direct hemoperfusion with a polymyxin B-immobilized
fiber column (PMX-DHP) improves oxygenation, but it is unclear whether treatment of AE-IPF with PMX-DHP affects
survival. This study elucidated the effectiveness and safety of PMX-DHP for the treatment of AE-IPF.
Methods: This study included 31 patients with 41 episodes of AE-IPF. All patients received steroids. Of 31, 14 patients
(20 episodes) were treated with PMX-DHP. The laboratory and physiological test results after the start of therapy and
survival were retrospectively compared between patients treated with and without PMX-DHP.
Results: Patients treated with PMX-DHP had a significantly greater change in PaO2/FiO2 ratio (mean ± SEM, 58.2 ± 22.5
vs. 0.7 ± 13.3, p = 0.034) and a smaller change in white blood cell count (−630 ± 959 /μL vs. 4500 ± 1190 /μL, p = 0.002)
after 2 days of treatment than patients treated without PMX-DHP. The 12-month survival rate was significantly higher in
patients treated with PMX-DHP (48.2% vs. 5.9%, p = 0.041). PMX-DHP was effective in patients with more severe
underlying disease (GAP stages II or III; 12-month survival rate 57.1% with PMX-DHP vs. 0% without PMX-DHP,
p = 0.021). Treatment with PMX-DHP was an independent predictor of better prognosis (hazard ratio 0.345, p = 0.037).
Mild pulmonary thromboembolism occurred in one patient treated with PMX-DHP.
Conclusions: Treatment of AE-IPF with PMX-DHP is tolerable and improves 12-month survival.
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Idiopathic pulmonary fibrosis (IPF) has a devastating
prognosis [1]. Kondoh et al. first described acute exacerba-
tion in IPF (AE-IPF) [2], which results in rapid deterior-
ation with a significant impact on the clinical course [3-5].
The most common pathological finding in AE-IPF is dif-
fuse alveolar damage (DAD) superimposed on usual inter-
stitial pneumonia (UIP)-pattern [3]. There is currently
no effective therapy for AE-IPF, and the prognosis is* Correspondence: norieno@hama-med.ac.jp
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unless otherwise stated.extremely poor [3,6-8]. Although steroids and immunosup-
presants are used for the treatment of AE-IPF, they do not
alter the natural course of the disease [8]. Novel methods of
treating AE-IPF are therefore being investigated.
Direct hemoperfusion with a polymyxin B-immobilized
fiber column (PMX-DHP) removes plasma endotoxins
from gram-negative bacteria, and is an effective treatment
for sepsis [9-11]. PMX-DHP therapy was also reported to
be beneficial in patients with gram-positive bacterial infec-
tions [10,11] and endotoxin-negative infections [12]. It is
noteworthy that PMX-DHP improves pulmonary oxygen-
ation in patients with acute respiratory distress syndrome
(ARDS), which is pathologically characterized by DADal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ation in patients with AE-IPF [15-18]. We recently re-
ported that PMX-DHP was beneficial in patients with
acute exacerbation of several types of interstitial pneumo-
nia including IPF [19], and that a longer duration of PMX-
DHP (12 hours) was more effective than a shorter duration
of PMX-DHP (≤6 hours) [20]. More recently, Abe et al.
reported a larger, multicenter, and retrospective study
of PMX-DHP in 160 patients with acute exacerbation of
interstitial pneumonia, including 73 patients with AE-IPF
[16]. In their study, survival rate at one month and three
months were 70.1% and 34.5%, respectively, in patients
with AE-IPF, and they concluded that treatment with
PMX-DHP for AE-IPF may improve the survival com-
pared to previous reports [16]. However, the precise sur-
vival benefit of treatment of AE-IPF with PMX-DHP
compared to treatment without PMX-DHP has not been
fully elucidated, and the indications for using PMX-DHP
are still unknown.
This study investigated the effectiveness and safety of
treatment of AE-IPF with PMX-DHP, and analyzed sur-
vival after treatment with and without PMX-DHP. This
study also sought to identify factors affecting survival
in patients with AE-IPF.
Methods
Study design and subjects
Thirty-one patients who were treated for AE-IPF at our
hospital between 1997 and 2013 were retrospectively
reviewed. Eight patients had two episodes of AE-IPF and
one patient had three episodes of AE-IPF (total, 41
episodes). Eighteen patients underwent surgical lung
biopsy (SLB) before developing AE-IPF, and met the 2011
consensus criteria for IPF of the American Thoracic Society
(ATS), European Respiratory Society (ERS), Japanese
Respiratory Society (JRS), and Latin American Thoracic
Association (ALAT) [1]. The remaining 13 patients had
typical clinical and high-resolution computed tomography
(HRCT) features of IPF and were diagnosed with IPF with-
out surgical lung biopsy [21]. Patients who met the criteria
for any connective tissue disorders were excluded from the
study, even if their histopathological examination showed
UIP. Histological diagnosis of UIP was in accordance with
previously published reports [1,22].
AE-IPF was diagnosed according to the modified
diagnostic criteria described by Collard et al. in 2007
[3]. Briefly, the criteria for diagnosis of AE-IPF were: 1)
previous or concurrent diagnosis of IPF, 2) unexplained
worsening or development of dyspnea within 30 days,
3) HRCT with new bilateral ground-glass abnormality
and/or consolidation superimposed on a background
reticular or honeycomb pattern, 4) no evidence of pul-
monary infection, and 5) exclusion of alternative causes
including left heart failure, pulmonary embolism, or anidentifiable cause of acute lung injury. Serum endotoxin
levels were below the level of detection in all patients
treated with PMX-DHP. The study protocol was approved
by the Ethical Committee of Hamamatsu University
School of Medicine (approval number 25–292).
Data collection
Clinical data, including sex, age, smoking-history, symp-
toms, treatments, and survival were obtained from the
medical records. Laboratory and pulmonary function test
results were also recorded. The severity of IPF before AE,
oxygenation and HRCT findings during AE, treatments
for AE, and survival were retrospectively reviewed. Disease
severity of IPF within 12 months before AE was assessed
using the GAP-staging system, which considers gender,
age, and two lung physiology variables: forced vital cap-
acity (FVC) and diffusion lung capacity for carbon monox-
ide (DLCO) [23].
Treatments of AE-IPF
Immediately after the diagnosis of AE-IPF, all patients
were started on high-dose corticosteroid pulse therapy
(methylprednisolone 1,000 mg/day for 3 days) followed by
a tapering dose of prednisolone with or without immuno-
suppresants (cyclophosphamide or cyclosporine). Some
patients also received intravenous sivelestat sodium
hydrate.
PMX-DHP therapy
Some patients were treated with PMX-DHP (PMX; Toray
Medical Co., Ltd, Tokyo, Japan) starting at the same time
as the corticosteroid and immunosuppressant therapy.
Starting in 2006, patients were treated with PMX-DHP
whenever practicable. Inclusion criteria of PMX-DHP for
the treatment of AE-IPF were as follows: 1) current diag-
nosis of AE-IPF, 2) able and willing to provide informed
consent. Exclusion criteria of PMX-DHP for the treatment
of AE-IPF were as follows: 1) ≥ 85 year-old, 2) history of
hypersensitivity for blood purification or extracorporeal
circulation therapy, 3) hemodynamic instability, 4) severe
cardiovascular disease, 5) severe hemorrhagic disease, 6)
terminal cancer, 7) pregnant or lactating, 8) considered in-
eligible for PMX-DHP by an attending doctor. A flow
chart of treatment with PMX-DHP according to these
inclusion and exclusion criteria is shown in Figure 1. A
total of 14 patients (20 episodes) were treated with PMX-
DHP. A double-lumen catheter was placed via a femoral
or internal jugular vein, and PMX-DHP was administered
for 6 or 12 hours (usually 12 hours) at a flow rate of
80–100 mL/minute. PMX-DHP was subsequently repeated
once or twice (usually once) within 24 hours. Nafamostat




Able and willing to provide 
informed consent
< Exclusion criteria of PMX-DHP >
1) 85 year-old 
2) history of hypersensitivity for blood purification 
or extracorporeal circulation therapy
3) hemodynamic instability
4) severe cardiovascular disease 
5) severe hemorrhagic disease 
6) terminal cancer 
7) pregnant or lactating 
8) considered ineligible for PMX-DHP by 
an attending doctor 
Figure 1 A flow chart of treatment with PMX-DHP. Patients who were diagnosed as AE-IPF received treatment with PMX-DHP according to
inclusion and exclusion criteria as written in “Methods” section.
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Blood samples were collected before and after PMX-DHP.
The serum level of angiopoietin-2 was measured using
enzyme-linked immunosorbent assay (R&D Systems, Inc.,
MN, USA).
Evaluation of HRCT findings
The extent of lung opacities was measured on three
HRCT slices: at the bifurcation of the trachea, at the
bases of the lower lobes, and at the midpoint between
the other two slices. The extent of fibrosis in each lobe
was scored using following system: 0, none; 1, 1–10%; 2,
11–25%; 3, 26–50%; 4, 51–75%; and 5, 76–100%. The
sum of the scores from five lobes (0–25) was used to
express the extent of reticular opacity, honeycombing,
consolidation opacity, and ground-glass opacity (GGO)
in each patient. The pattern of AE-IPF on HRCT was
classified as 1) peripheral, 2) multifocal, or 3) diffuse as re-
ported by Akira [24]. The HRCT findings were reviewed
by two observers, and the rate of agreement between ob-
servers were evaluated by weighted-kappa coefficients.
The coefficients were between 0.52 and 0.56. If the score
differed between observers, a consensus was reached after
discussion.
Statistical analysis
Statistical analyses were performed using StatView J-4.5
(SAS Institute Inc; Cary, NC, USA). Categorical data were
compared using the Chi-square test or Fisher’s exact prob-
ability test for independence, and continuous data were
compared using the paired t-test. Overall survival ofpatient groups was estimated using Kaplan-Meier curves,
and was compared between groups using the log-rank test.
The relationships between variables, including treatment
with PMX-DHP and mortality, were evaluated using Cox’s
proportional hazards regression analysis. All tests were
two-sided and statistical significance was set at p < 0.05.
Results
Demographic, laboratory, and physiological data
The clinical characteristics of the patients, including the
laboratory and physiological test results at the time of the
first AE-IPF, are shown in Table 1. The median age of the
patients was 69 years, and 28 patients were male. The
median observation period was 53 months. The percent
predicted FVC (%FVC) and percent predicted DLCO
(%DLCO) within 12 months before AE-IPF were moder-
ately impaired (median, 58.8% and 57.1%, respectively).
The minimum SpO2 and the distance walked in the
6-minute walk test (6MWT) were also impaired (median,
82% and 360m, respectively). The severity of IPF within 12
months before AE-IPF was staged using the GAP system
[23]. The most common GAP grade was III (the most
severe stage), accounting for 10 patients (32.3%). Eighteen
of 31 patients (58.1%) received treatment for IPF before
AE-IPF, including steroids, immunosuppresants, and pirfe-
nidone. Nine patients (29.0%) received long-term oxygen
therapy before AE-IPF. The mortality rate was 38.7% at 3
months after AE-IPF and 74.2% at 12 months after AE-
IPF. Fourteen patients (45.2%) were treated with PMX-
DHP for 20 episodes of AE-IPF and 17 patients (54.8%)
were treated without PMX-DHP for 21 episode of AE-IPF.
Table 1 Clinical characteristics, laboratory and
physiological test results in all patients with IPF
Median (range), n = 31
Age, years 69 (50, 84)
Sex, male/female 28/3
Smoking, never/ex/current 4/23/4
Pack-year of smoking 35 (0, 81)
Diagnosis, surgical lung biopsy/clinical, n 18/13
Period from symptom onset, m 49 (0, 203)
Observation period, m 53 (2, 205)
%FVC before AE, % 58.8 (37.5, 89.3)
FEV1% before AE, % 87.4 (78.5, 107.0)
%DLCO before AE, % 57.1 (33.5, 88.2)
PaO2 at rest before AE, Torr 70.5 (49.0, 91.0)
6MWT distance before AE, m 360 (160, 507)
6MWT minSpO2 before AE, % 82 (60, 87)
Serum LDH at AE, ng/mL 344 (220, 602)
Serum KL-6 at AE, U/mL 1367 (481, 6404)
Serum SP-D at AE, ng/mL 339 (23, 966)
Extent scores on HRCT before AE
(full score: 25)
12 (7, 19)
The GAP staging system before
AE, I/II/III/unknown
8/7/10/6
Preceding treatments for IPF, +/ - 18/13
Preceding oxygen therapy, +/ - 9/22
Period from admission to commencement
of treatments for AE, day
1 (0, 17)
Treatment with PMX-DHP, +/- 14/17
Mortality 3 months after AE, n (%) 12 (38.7)
Mortality 12 months after AE, n (%) 23 (74.2)
AE = acute exacerbation; IPF = idiopathic pulmonary fibrosis; FVC = forced
vital capacity;
FEV1 = forced expiratory volume in 1 second; DLCO: diffusion lung capacity for
carbon monoxide; 6MWT = six-minute walk test; LDH = lactate dehydrogenase;
KL-6 = Krebs von den Lungen-6; SP-D = surfactant protein D; PMX-DHP = direct
hemoperfusion with a polymyxin B-immobilized fiber column.
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after 2006 (2009–2012). One of them was aged 84-year old
and had advanced-lung cancer. Another patient had severe
cardiac disease. Another three patients received long-term
oxygen therapy and had poor activity of daily living due to
slowly progressive IPF before AE-IPF. Therefore, these 5
patients were considered ineligible for PMX-DHP. The
other one patient showed good response to treatment with
steroids and did not need further PMX-DHP.
Comparisons between patients treated with and without
PMX-DHP
The demographic data, preceding IPF treatment, labora-
tory and physiological tests results, HRCT findings, and
treatment for AE-IPF in patients treated with and withoutPMX-DHP are shown in Table 2. There were no signifi-
cant differences between the two groups. Although pa-
tients treated with PMX-DHP tended to have a lower
GAP-stage before AE-IPF, there were no significant differ-
ences before AE-IPF in PaO2 at rest, 6MWT results,
serum levels of Krebs von den Lungen-6 (KL-6) and sur-
factant protein D (SP-D), or extent score based on HRCT
between the two groups. There were also no significant
differences in PaO2/FiO2 (P/F) ratio at the time of AE-IPF,
time from admission to the start of treatment for AE-IPF,
HRCT-patterns at the time of AE-IPF, administration of
corticosteroids, immunosuppresants and other agents, or
intubation rate between the two groups. Serum endotoxin
levels were below the level of detection in all patients
treated with PMX-DHP.
PMX-DHP
The details of PMX-DHP are shown in Table 3. Eighteen
of 20 episodes of AE-IPF (90%) were treated with 12-hour
periods of PMX-DHP and the remaining 2 episodes (10%)
were treated with 6-hour periods of PMX-DHP. Nineteen
episodes (95%) of AE-IPF were treated with two periods of
PMX-DHP and the other episode was treated with three
periods of PMX-DHP. The median time from admis-
sion to the start of PMX-DHP was one day. The antico-
agulants administered were nafamostat mesilate for 17
episodes of AE-IPF and heparin sodium for 3 episodes
of AE-IPF. Thrombomodulin-α was administered to
one patient, who did not receive PMX-DHP. Mild pul-
monary thromboembolism occurred in one patient,
which resolved after anticoagulant therapy. No other
adverse events were observed, and PMX-DHP therapy
was tolerable in all patients.
Effects of treatment with PMX-DHP on acute phase of AE-IPF
Changes after 2 days of treatment were compared between
patients treated with and without PMX-DHP (Figure 2).
In the PMX-DHP group, steroid-pulse therapy and PMX-
DHP were started simultaneously in 17 of the 20 episodes
(85.0%). Change in P/F ratio (ΔP/F ratio; P/F ratio 2 days
after the start of treatments – P/F ratio just before treat-
ments) was significantly greater in patients treated with
PMX-DHP than in patients treated without PMX-DHP
(mean ± standard error of the mean, 58.2 ± 22.5 vs. 0.7 ±
13.3, p = 0.034; Figure 2A). Patients treated with PMX-
DHP also had a significantly smaller change in white
blood cell count (−630 ± 959/μL vs. 4500 ± 1190 /μL,
p = 0.002; Figure 2B) and change in neutrophil count
(1095 ± 1649/μL vs. 6166 ± 1406/μL, p = 0.031; Figure 2C)
than patients treated without PMX-DHP. Patients treated
with PMX-DHP also had a significant smaller change in
platelet count than patients treated without PMX-DHP
(−5.4 ± 0.7 × 104/μL vs. -0.9 ± 1.5 × 104/μL, p = 0.010;
Figure 2D), and there were no episodes of bleeding.
Table 2 Comparisons between patients treated with and without PMX-DHP
PMX-DHP –(median (range), n = 17) PMX-DHP + (median (range), n = 14) p value
Age, years 71 (50, 84) 66.5 (52, 81) 0.109
Sex, male/female 15/2 13/1 0.999
Smoking, never/ex/current 3/13/1 1/10/3 0.346
Pack-year of smoking 25 (0, 80) 45 (0, 81) 0.086
Period from symptom onset to AE, mo 72 (0, 203) 30 (2, 156) 0.082
Observation period, mo 66 (9, 205) 50 (2, 162) 0.463
%FVC before AE, % 46.7 (37.5, 89.3) 61.9 (40.7, 88.0) 0.136
FEV1% before AE, % 87.5 (79.7, 100.0) 87.4 (78.5, 107.0) 0.769
%DLCO before AE, % 57.1 (33.5, 88.2) 62.0 ( 44.0, 77.8) 0.892
PaO2 at rest before AE, Torr 68.5 (53.9, 86.6) 72.8 (49.0, 91.0) 0.978
6MWT distance before AE, m 375 (160, 465) 365 (175, 507) 0.523
6MWT minSpO2 before AE, % 82 (62, 83) 82 (60, 87) 0.721
Serum LDH at AE, IU/L 322 (220, 601) 347 (277, 602) 0.409
Serum KL-6 at AE, U/mL 1367 (634, 3160) 1690 (481, 6404) 0.174
Serum SP-D at AE, ng/mL 295 (24, 645) 469 (102, 966) 0.159
Extent scores on HRCT before AE (full score: 25) 11.5 (7, 19) 13 (7, 15) 0.624
HRCT-patterns at AE, peripheral/multifocal/diffuse/
unknown
1/2/13/1 3/1/10/0 0.483
The GAP staging system before AE, I/II/III/unknown 2/3/7/5 6/5/3/0 0.059
Preceding treatment for IPF, +/- 10/7 8/6 0.925
Preceding oxygen therapy, +/- 5/12 4/10 0.999
P/F ratio at AE 162 (44, 316) 171 (31, 368) 0.741
Extent scores on HRCT at AE (full score: 25) 20 (13, 25) 20.5 (14, 25) 0.915
Period from admission to commencement of
treatments for AE, day
1 (0, 6) 0.5 (0, 17) 0.755
Administration of steroid-pulse therapy for AE, +/- 17/0 14/0 NS.
Administration of Immunosuppresants for AE, +/- 12/5 9/5 0.709
Administration of Sivelestat sodium hydrate for
AE, +/-
3/14 5/9 0.413
Intubation at AE, +/- 3/14 5/9 0.413
PMX-DHP = direct hemoperfusion with a polymyxin B-immobilized fiber column; AE = acute exacerbation; IPF = idiopathic pulmonary fibrosis; FVC = forced vital
capacity; FEV1 = forced expiratory volume in 1 second; DLCO = diffusion lung capacity for carbon monoxide; 6MWT = six-minute walk test; LDH = lactate dehydrogenase;
KL-6 = Krebs von den Lungen-6; SP-D = surfactant protein D; HRCT = high-resolution computed tomography; P/F = PaO2/FiO2.
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serum lactate dehydrogenase level between the two
groups (Figure 2E). In patients treated with PMX-
DHP, P/F ratio increased significantly after 2 days
(p = 0.026; Figure 3A) and the serum angiopietin-2
level, which is related to vascular permeability [25],
decreased significantly after 2 days (p = 0.022; Figure 3B).
Effects of treatment with PMX-DHP on survival
Twenty -three of the 31 patients (74.2%) died within 12
months of the first episode of AE-IPF. Eighteen patients
died of respiratory failure, four died of infection, and
one died of an unknown cause. The Kaplan-Meier sur-
vival curves from the time of AE-IPF are shown inFigure 4. The 12-month survival rate was significantly
better in patients treated with PMX-DHP than in
patients treated without PMX-DHP (48.2% vs. 5.9%,
log-rank test, p = 0.041). Interestingly, the survival benefit
of treatment with PMX-DHP was evident from 3 months
after the time of AE-IPF. The results of univariate Cox
proportional hazards analyses to identify factors that pre-
dicted prognosis are shown in Table 4. Treatment with
PMX-DHP was significantly associated with a more favor-
able prognosis (hazard ratio [HR] 0.399, p = 0.047). The
prognosis was also significantly associated withΔP/F ratio
(HR 0.990, p = 0.008) andΔLDH (HR 1.006, p = 0.009).
Multivariate Cox proportional hazards analysis adjusted
























































Figure 2 Comparisons after 2 days of treatment between patients tre
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C) Changes in the neutrophil count (ΔNeut). D) Changes in the platelet co
There were significant differences in ΔP/F ratio, ΔWBC, ΔNeut, and ΔPlt (al
Table 3 Details of PMX-DHP and adverse events
PMX-DHP (n = 14,
20 episodes)
Perfusion duration, 6h/12h 2/18
Cycles of perfusion, 2 times/3 times 19/1
Interval of each perfusion, 12h/18h 18/2





PMX-DHP = direct hemoperfusion with a polymyxin B-immobilized fiber column.
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associated with treatment with PMX-DHP (HR 0.345,
p = 0.037), ΔP/F ratio (HR 0.989, p = 0.004), andΔLDH
(HR 1.007, p = 0.007) (Table 5).
Survival curves according to the severity of disease
before AE-IPF showed that patients with less severe
IPF (GAP-stage I) did not have a significant benefit
from treatment with PMX-DHP (PMX-DHP+: HR 0.892,
p = 0.896; log-rank test, p = 0.896; Figure 5A), whereas
patients with more severe IPF (GAP-stage II and III) had
significantly better survival if they were treated with
PMX-DHP (PMX-DHP+: HR 0.226, p = 0.031; log-rank
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in patients treated with PMX-DHP and 0% in patients
treated without PMX-DHP. In this study, 6 patients
without PMX-DHP treatment satisfied exclusion cri-
teria. To reduce this bias in non-PMX group, we ex-
cluded these 6 patients applying exclusion criteria from
the analysis. We compared survival curves between 14
patients with PMX-DHP treatment and 11 patients
without PMX-DHP treatment, who did not meet exclu-
sion criteria. Although the difference was not signifi-
cant, patients treated with PMX-DHP tended to have
better survival than those treated without PMX-DHP
(Additional file 1: Figure S1, 12-month survival rate,
48.2% vs. 9.1%; log-rank test, p = 0.115). Furthermore,
in 12 patients with GAP-stage II or III disease who did
not meet exclusion criteria, patients had a significant
benefit from treatment with PMX-DHP (Additional
file 2: Figure S2, 12-month survival rate, 57.1% vs. 0%;
log-rank test, p = 0.048).
Discussion
Acute exacerbation is common in patients with IPF, with a
reported rate of 8.6-14.2% per year [4,8]. Acute exacerba-
tion has a significant impact on survival, and contributes
to the grim prognosis of IPF [1,4,8]. There is currently no
effective treatment for AE-IPF, including steroid therapy
[8], and the prognosis of AE-IPF is extremely poor [3,5-8].
Development of a novel method of treatment for IPF-AE
is therefore desirable. This study found that treatment for
AE-IPF with PMX-DHP was safe without severe adverse
events, and that 12-month survival rate was significantly















Figure 3 Changes in PaO2/FiO2 ratio and angiopoietin-2 after 2 days
PaO2/FiO2 (P/F) ratio. B) Changes in the serum level of angiopietin-2 lev
(both p < 0.05). The horizontal bars indicate the median values.treated without PMX-DHP. The effects of treatment with
PMX-DHP were evident in patients with a more severe
stage of IPF, and treatment of AE-IPF with PMX-DHP was
associated with a favorable outcome.
We previously reported the beneficial effects of treatment
with PMX-DHP for acute exacerbation of several interstitial
pneumonias including AE-IPF, and improved oxygenation
in patients treated with PMX-DHP [19]. More recently,
Abe et al. reported a larger, multicenter, and retrospective
study, which found that treatment with PMX-DHP may
improve the survival in patients with AE-IPF compared to
previous reports [16]. The precise mechanism by which
PMX-DHP improves oxygenation in patients with AE-IPF
is unknown. Abe et al. reported that activated neutrophils
were adsorbed by the PMX-column [26], and that the white
blood cells count decreased after PMX-DHP [16]. The
present study also found significantly decreased white
blood cell and neutrophil counts in patients treated
with PMX-DHP than in patients treated without PMX-
DHP. Treatment of AE-IPF or septic shock with PMX-
DHP has also been reported to decrease the concentrations
of serum matrix metalloproteinase (MMP)-9 [26], vascular
endothelial growth factor (VEGF) [27], and angiopoietin-2
[28,29], which can facilitate vascular permeability. Direct
interactions between activated neutrophils and endo-
thelial cells can induce production of angiopoietin-2 by
endothelial cells [30]. In the present study, the serum
level of angiopoietin-2 was significantly decreased after
treatment with PMX-DHP. These treatment effects may
be associated with changes in vascular permeability. The
relationships between PMX-DHP and factors that facilitate
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log-rank,  p = 0.041
PMX-DHP -
PMX-DHP +
Figure 4 Kaplan-Meier survival curves showing the effects of treatment of AE-IPF with PMX-DHP on survival. Patients treated with PMX-DHP
had significantly better survival than patients treated without PMX-DHP (48.2% vs. 5.9%; log-rank test, p = 0.041).
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DHP on their survival has been unclear. The previously
reported 12-month survival rate after AE-IPF was about
20% [7,8]. In the present study, the 12-month survival rate
was 48.2%, and survival was significantly better in patients
treated with PMX-DHP than in patients treated without
PMX-DHP. To the best of our knowledge, this is the first
study to show that treatment of AE-IPF with PMX-DHP
significantly improves survival compared to that without
PMX-DHP.
Abe et al. reported a 3-month survival rate of 34.5% in
patients treated for AE-IPF with PMX-DHP, which is bet-
ter than in previous reports [16]. The present study found
an even higher 3-month survival rate (61.3%) after treat-
ment with PMX-DHP. This may be because of differences
in the duration and timing of PMX-DHP between the
two studies. Most patients in the present study received
12-hour periods of PMX-DHP, whereas most patients
in the study by Abe et al. received 6-hour periods of
PMX-DHP. We recently reported that a longer duration
of PMX-DHP (12 hours) was more effective than a
shorter duration of PMX-DHP (≤6 hours) [20]. As for
timing, time from hospital admission to the start of
PMX-DHP was short in the present study (median, one
day). PMX-DHP was started as soon as possible in this
study, at the same time as steroid-pulse therapy in 17
of the 20 episodes (85.0%), whereas PMX-DHP was started
after the start of steroid therapy in the majority of patients
(98%) in the study by Abe et al. [16]. These differences in
the duration and timing of PMX-DHP may have resulted
in better survival in the present study.
Interestingly, this study showed a difference in survival
from 3 months after the start of treatment for AE-IPF. Themechanisms underlying this phenomenon are unknown.
Oishi et al. reported that PMX-fiber removed profibro-
tic cytokines such as fibroblast growth factor (FGF),
platelet-derived growth factor (PDGF), and transform-
ing growth factor-β (TGF-β) in patients with AE-IPF
[27]. Therefore, removal of these profibrotic cytokines
may have improved the survival rate in fibrotic phase in
patients treated with PMX-DHP. Alternatively, only sur-
vived patients, whose pulmonary reserve capacity strik-
ingly decreased, at 3 months from the onset of AE-IPF
may have been benefited from treatment with PMX-
DHP. Further studies are needed to clarify the mecha-
nisms underlying these findings.
The severity of IPF before AE-IPF was evaluated
using the GAP staging system. The GAP system is an
easy and reliable method of staging the severity of IPF
[23], that considers of gender, age, and two lung physi-
ology variables (%FVC and %DLCO). In the present
study, patients with more severe disease (GAP stage II
or III) had better survival after treatment with PMX-
DHP. This result may imply an early treatment of
AE-IPF with PMX-DHP in patients with advanced IPF.
However, patients with less severe disease (GAP stage
I) consist of only eight, and further study is needed to
clarify this issue.
In the analysis of prognostic factors, PMX-DHP, ΔP/F
ratio, and ΔLDH were significantly associated with a
more favorable prognosis. However, there was no differ-
ence in ΔLDH between PMX and non-PMX groups. We
suspect that slight hemolysis may have occurred in
patients treated with PMX-DHP, and this hemolysis may
be why ΔLDH was equivalent between PMX and non-
PMX groups.
Table 4 Univariate Cox proportional hazards analyses for survival
Variable Hazard ratio 95% CI p value
Lower Upper
Age at biopsy, yr 1.040 0.977 1.108 0.220
Sex, female 0.432 0.122 1.526 0.193
Pack-year of smoking 0.993 0.978 1.008 0.367
Symptom onset, mo 1.001 0.994 1.009 0.737
Extent score on HRCT before AE 1.127 0.970 1.311 0.119
FVC before AE, % pred 0.989 0.956 1.023 0.514
FEV1/FVC, % 0.953 0.877 1.035 0.249
DLCO before AE, % pred 0.987 0.958 1.018 0.416
Resting PaO2, mmHg 0.999 0.961 1.039 0.961
Distance in six-minute walk test 0.998 0.992 1.005 0.609
Minimum SpO2 in six-minute walk test 0.960 0.884 1.043 0.338
Serum LDH, IU/L 1.003 0.997 1.008 0.305
Serum KL-6, U/mL 1.000 1.000 1.000 0.447
Serum SP-D, ng/mL 0.999 0.997 1.001 0.256
The GAP staging system before AE 1.089 0.639 1.854 0.754
Preceding treatments for IPF, + 0.913 0.399 2.088 0.829
Preceding oxygen therapy, + 1.662 0.678 4.074 0.267
P/F ratio at AE 0.999 0.994 1.003 0.565
Extent score on HRCT at AE 1.077 0.954 1.215 0.231
Period from admission to commencement of treatments for AE, day 1.104 0.985 1.237 0.090
Administration of Immunosuppressant for AE, + 1.403 0.548 3.593 0.481
Administration of Sivelestat sodium hydrate for AE, + 0.787 0.290 2.131 0.637
PMX-DHP, + 0.399 0.161 0.988 0.047
ΔWBC 2 days after commencement of treatments for AE, /μL 1.000 1.000 1.000 0.423
ΔNeutrophil 2 days after commencement of treatments for AE, /μL 1.000 1.000 1.000 0.607
ΔP/F ratio 2 days after commencement of treatments for AE 0.990 0.983 0.997 0.008
ΔLDH 2 days after commencement of treatments for AE, IU/L 1.006 1.002 1.011 0.009
ΔAngiopoietin-2 2 days after commencement of treatments for AE, pg/mL 1.000 1.000 1.001 0.307
AE = acute exacerbation; IPF = idiopathic pulmonary fibrosis; FVC = forced vital capacity;
FEV1 = forced expiratory volume in 1 second; DLCO = diffusion lung capacity for carbon monoxide; 6MWT = six-minute walk test; LDH = lactate dehydrogenase;
KL-6 = Krebs von den Lungen-6; SP-D = surfactant protein D; P/F = PaO2/FiO2; HRCT = high-resolution computed tomography; PMX-DHP = direct hemoperfusion
with a polymyxin B-immobilized fiber column.
Table 5 Multivariate Cox proportional hazards analysis for survival adjusted for GAP-stage
Variable Hazard ratio 95% CI p value
Lower Upper
Extent score on HRCT before AE 1.177 0.982 1.409 0.078
Period from admission to commencement of treatments for AE, day 1.092 0.974 1.224 0.132
PMX-DHP, + 0.345 0.127 0.936 0.037
ΔP/F ratio 2 days after commencement of treatments for AE 0.989 0.982 0.997 0.004
ΔLDH 2 days after commencement of treatments for AE, IU/L 1.007 1.002 1.013 0.007
AE = acute exacerbation; HRCT = high-resolution computed tomography; PMX-DHP = direct hemoperfusion with a polymyxin B-immobilized fiber column;
P/F = PaO2/FiO2; LDH = lactate dehydrogenase.



























































Figure 5 Survival curves according to the severity of IPF during the 12 months before AE-IPF. A) Patients with GAP stage I disease. B)
Patients with GAP-stage II or III disease (log-rank test, p = 0.021). In patients with more severe disease (GAP-stage II or III), the 12-month survival
rate was significantly higher in those who were treated with PMX-DHP than in those who were treated without PMX-DHP (57.1% vs. 0%).
Enomoto et al. BMC Pulmonary Medicine  (2015) 15:15 Page 10 of 11This study has a number of limitations. First, only a
small number of patients with AE-IPF were included.
Second, the data were collected retrospectively. Third,
the treatment for AE-IPF other than PMX-DHP and ste-
roids was not uniform. Finally, AE-IPF in a Japanese
population may not be the same as that in other ethnic
groups [31]. AE-IPF is the most common cause of death
in Japanese patients with IPF (40%) [32], and this inci-
dence is higher than that in western countries (30%)
[33]. This discrepancy in the incidence of AE-IPF may
indicate an ethnic difference. Therefore, the response to
treatment with PMX-DHP may be different between
Japanese and other ethnic groups. A larger and prospect-
ive cohort study should therefore be conducted to further
evaluate the treatment of AE-IPF with PMX-DHP.
Conclusions
The present study found that treatment of AE-IPF with
PMX-DHP was safe, was not associated with severe ad-
verse events, and improved oxygenation. The 12-month
survival rate was better in patients treated with PMX-
DHP than in patients treated without PMX-DHP. The
effects of treatment with PMX-DHP were evident in
patients with a more severe stage of IPF. Treatment with
PMX-DHP was also a favorable prognostic factor in
patients with AE-IPF. Recent randomized controlled tri-
als reported promising results using novel medications
for chronic stage of IPF, such as nintedanib and pirfeni-
done [34,35]. However, there is still no effective treat-
ment for AE-IPF, which worsens the overall prognosis ofIPF [4]. Treatment of AE-IPF with PMX-DHP may im-
prove the clinical course of this severe condition, and
may improve the overall survival of patients with IPF. A
larger prospective controlled trial is needed to further
evaluate the treatment of AE-IPF with PMX-DHP.
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